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Addressing Looming Prescription Drug 
Shortages Through Legislative and Regulatory 
Approaches 
Eric Friske* 
INTRODUCTION 
An alarming increase in drug shortages in recent years 
presents a crisis affecting medical facilities across the nation, 
compromising patient care in a wide variety of serious illness-
es. Many of the medications affected by these shortages are 
critical products, including oncology drugs, anesthetics, and an-
timicrobials.1 Over ninety-three percent of drugs shortages dur-
ing 2010 and 20112 were classified as “medically-necessary” 
drugs required “to treat or prevent a serious disease or medical 
condition for which there is no other adequately available drug 
product” to act as an appropriate substitute.3 
The frequency of drug shortages has steadily increased 
since 2005, nearly tripling over the span of five years.4 The 
Food and Drug Administration (FDA) defines a drug shortage 
as “a situation in which the total supply of all clinically inter-
changeable versions of an FDA-regulated drug is inadequate to 
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 1. Matthew T. Corso, Crisis Averted? Manufacturers Scurry to Meet De-
mand for Drugs, ONCLIVE (Mar. 12, 2011), http://www.onclive.com 
/publications/obtn/2011/march-2011/crisis-averted-manufacturers-scurry-to-
meet-demand-for-drugs. 
 2. FDA, A REVIEW OF FDA’S APPROACH TO MEDICAL PRODUCT 
SHORTAGES 13 (2011) [hereinafter FDA’S APPROACH] available at 
http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UC
M277755.pdf. 
 3. OFFICE OF NEW DRUGS, DRUG SHORTAGE MANAGEMENT 8 (2012), 
available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/ 
StaffPoliciesandProcedures/ucm079936.pdf. 
 4. Doug Trapp, Despite FDA Efforts, Shortages of Drugs Tripled in 5 
Years, AMEDNEWS.COM (Oct. 3, 2011), http://www.ama-assn.org/amednews/ 
2011/10/03/gvl21003.htm. 
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meet the current or projected demand” at the patient level.5 
The Center for Drug Evaluation and Research (CDER) reported 
178 drug shortages in 2010,6 and a record 267 shortages were 
reported in 2011,7 as compared to just 61 in 2005.8 
According to the FDA, the majority of drug shortages in-
volve generic sterile injectables, accounting for approximately 
seventy-four percent of all reported shortages.9 Sterile injecta-
bles are potentially at a greater risk of shortage, as compared 
to oral drugs, because of the more complex and specialized pro-
cess required for manufacturing. Because the manufacturing 
process of sterile injectables is complex, shortages involving 
these drugs can last for months.10 Of the drug shortages re-
ported since the beginning of 2010, approximately fifty percent 
were generic or unapproved drugs.11 
This Note proceeds in two parts. Part I provides back-
ground on the recent drug shortage problems afflicting patients 
and medical facilities throughout the country and the current 
and proposed regimes available to address these problems. Part 
I.A provides background on the numerous underlying causes of 
drugs shortages, including the role of raw material supplies 
and manufacturing capabilities, and Part I.B examines the 
subsequent impact of shortages on patient care and the re-
sources of medical facilities. Part I.C, Part I.D, and Part I.E ex-
plain the FDA’s existing drug shortage program, provide back-
ground on both the pending legislation in Congress meant to 
address current and future shortages, and the recent executive 
order issued in response to the shortage problem, respectively. 
Part II of this Note provides analysis of the proposed legislation 
for addressing the drug shortage problem and provides addi-
                                                          
 5. OFFICE OF NEW DRUGS, supra note 3, at 7. 
 6. FDA and Manufacturers Work to Prevent Drug Shortages, U.S. FOOD 
& DRUG ADMIN., http://www.fda.gov/Drugs/DrugSafety/DrugShortages/ 
ucm257746.htm (last updated June 9, 2011). 
 7. Awi Federgruen, The Drug Shortage Debacle—And How to Fix It, 
WALL ST. J., Mar. 2, 2012, at A13. 
 8. FDA and Manufacturers Work to Prevent Drug Shortages, supra note 
6. 
 9. FDA’S APPROACH, supra note 2, at 13. 
 10. See id. Shortages involving oral drugs are typically resolved more rap-
idly than sterile injectables. Id. 
 11. Id. at 14. Unapproved drugs are generally older drugs that have been 
marketed without required FDA approval. Id. 
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tional, alternative approaches for mitigating the occurrence 
and severity of shortages. This Note concludes that existing leg-
islation makes important steps in assisting the FDA to ade-
quately manage these shortages, but ultimately falls short of 
providing the multifaceted approach necessary to address the 
many underlying problems influencing these shortages. 
I. BACKGROUND 
A. CAUSES OF DRUG SHORTAGES 
Although it is difficult to determine a singular causative 
agent of drug shortages, there are many underlying factors con-
tributing to decreased availability. Often, these factors are a 
combination of perturbed supply, manufacturing capacity, and 
utilization. 
1. Supply of Raw Materials 
Changes in the supply levels of raw materials necessary for 
the manufacture of drug products may contribute to the crea-
tion of shortages. Essential raw materials, sometimes referred 
to as the “active pharmaceutical ingredients” (API), are neces-
sary components for the synthesis of final drug products.12 
Even though there may exist multiple manufacturers of a par-
ticular drug product, there may be few, or even just one, sup-
plier of the API.13 Any interruptions in supply will inevitability 
exert downstream effects on the manufacturer’s ability to pro-
duce final products, potentially leading to a drug shortage.14 
Certain externalities, including political upheaval, disease, or 
environmental conditions can also perturb the availability of 
raw materials.15 
                                                          
 12. See Examining the Increase in Drug Shortages: Hearing Before H. 
Comm. on Energy & Commerce Subcomm. on Health, 112th Cong. 3 (2011) 
(testimony of Jonathan Kafer, Vice President Sales & Marketing, Teva Health 
Systems), available at http://democrats.energycommerce.house.gov/sites 
/default/files/image_uploads/Kafer_Testimony_HE_09.23.11.pdf. 
 13. See id. 
 14. See id. at 3–4. Inadequate supply levels could be the result of in-
creased demand for particular drugs and insufficient ability to increase pro-
duction or availability of necessary raw materials, or instead could be the re-
sult of decreased supply as a result of decreases in supply level due to 
bankruptcy, changes in production, or other externalities. See id. 
 15. Erin R. Fox et al., ASHP Guidelines on Managing Drug Product 
Shortages in Hospitals and Health Systems, 66 AM. J. HEALTH-SYS. PHARMACY 
1399, 1400 (2009). 
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Disturbances in the quality of API may similarly contrib-
ute to the prevalence of shortages.16 In 2010, at least 42% of 
sterile injectable drug shortages were caused by contamination 
or stability changes, 9% of which were attributable to the quali-
ty of raw materials.17 Problems with drug quality at manufac-
turing sites which resulted in disruption are one of the most 
prominent causes of drug shortages.18 As much as 80% of raw 
drug materials are procured from foreign markets, and in re-
cent years, there has been an increasing wariness regarding 
the quality of these materials.19 
2. Manufacturer Production Capabilities 
Drug shortages may also occur when the manufacturer of a 
particular drug product halts production as a result of an FDA 
enforcement action for noncompliance with current good manu-
facturing practices (cGMP) or because of voluntary product dis-
continuation.20 Factors contributing to noncompliance may 
vary from loss of personnel to antiquated manufacturing 
equipment, and could involve a long and demanding process to 
resolve.21 The resolution of these compliance issues, which 
could also include injunctions or seizure of products, may ulti-
mately prevent production for a significant period of time and 
become a significant contributing factor toward the develop-
ment of a shortage.22 
Alternatively, a manufacturer’s decision to voluntarily 
close a manufacturing facility or discontinue a product could 
                                                          
 16. See COLEEN CHERICI ET AL., NAVIGATING DRUG SHORTAGES IN 
AMERICAN HEALTHCARE: A PREMIER HEALTHCARE ALLIANCE ANALYSIS 1 
(2011), available at http://www.premierinc.com/about/news/11-mar/drug-
shortage-white-paper-3-28-11.pdf. 
 17. Id. 
 18. See FDA and Manufacturers Work to Prevent Drug Shortages, supra 
note 6. The nature of these quality problems is typically severe. “In general, 
inspection findings that have been followed by shortages have been serious in 
nature: glass shards, metal filings, and fungal or other contamination in in-
jectable products that must be sterile and pure to be safe for patients.” FDA’S 
APPROACH, supra note 2, at 35. 
 19. See CHERICI ET AL., supra note 16, at 2. 
 20. Id. at 3. 
 21. See FDA’S APPROACH, supra note 2, at 35. 
 22. See Facts About Current Good Manufacturing Practices (cGMPs), U.S. 
FOOD & DRUG ADMIN., http://www.fda.gov/drugs/developmentapprovalprocess/ 
manufacturing/ucm169105.htm (last updated June 25, 2009). 
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also have the unintended consequence of creating a drug short-
age.23 Increasing financial pressures may provide significant 
impetus for a manufacturer to discontinue a drug product line 
in favor of a more lucrative alternative.24 Even in the absence 
of more lucrative options, the potential profitability of a partic-
ular drug might simply be insufficient to justify production. For 
example, pragmatic manufacturers might conclude that the 
high costs associated with meeting safety requirements and 
regulatory user fees exceed projected profits based on the ex-
pected market demand.25 Under the current regulatory regime, 
manufacturers are not required to notify the FDA about their 
plans to discontinue production unless the drug is life-
supporting, life-sustaining, or used to prevent a debilitating 
disease or condition, and the manufacturer is the sole source of 
production.26 
Recent economic constraints have further contributed to 
drug shortage risks by leading many drug manufacturers to 
employ leaner inventories, reducing the overall stockpiles of 
drug ingredients.27 Although the effect of this trimming process 
is to improve capital efficiency for the firm, it simultaneously 
reduces the manufacturer’s ability to respond to fluctuations 
within the pharmaceutical market and creates greater risk as-
sociated with the potential unavailability of necessary drug in-
gredients.28 
B. IMPACT OF DRUG SHORTAGES 
1. Patient Care Impact 
Shortages in the supply of critical drugs have potentially 
dangerous effects on the administration of patient care. The 
unavailability of necessary medications may force physicians to 
cease or delay important procedures or employ less effective al-
ternatives.29 There also exists the risk that physicians may not 
                                                          
 23. See CHERICI ET AL., supra note 16, at 1–2. 
 24. Fox et al., supra note 15, at 1400–01. 
 25. See CHERICI ET AL., supra note 16, at 1–2. 
 26. See id. 
 27. See id. at 2. 
 28. See id. 
 29. Consider, for example, the specific case of Bleomycin at the Lancaster 
General Health Hospital. Bleomycin is a drug that is “critical to curative ther-
apies for Hodgkin’s lymphoma (ABVD regimen) and testicular cancer (BEP 
regimen), especially for young adult patients with curative diseases and good 
performance status.” Examining the Increase in Drug Shortages: Hearing Be-
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be as knowledgeable about alternative products. This increases 
the probability for dosing errors and preventable adverse reac-
tions between drug products.30 
In some instances, drug shortages may effectively deny pa-
tients access to curative therapy and leave them with no mean-
ingful alternatives.31Aside from the potential psychological and 
emotional impact on patients who are unable to receive neces-
sary treatment, even when substitute drugs are available, 
there is often less data available to the physician regarding the 
use of the product.32 This is particularly relevant when the un-
available drug has historically represented the gold standard 
treatment for a particular condition to the exclusion of other 
drugs whose risks and outcomes are less attractive.33 
2. Financial Impact 
Drug shortages can impose significant financial impacts on 
                                                          
fore the H. Comm. on Energy & Commerce Subcomm. on Health, 112th Cong. 5 
(2011) (testimony of Richard D. Paolotti, Vice President Operations- Pharma-
cy, Laboratory, and Radiology Lancaster General Health), available at 
http://democrats.energycommerce.house.gov/sites/default/files/image_uploads/
Paoletti_Testimony_HE_09.23.11.pdf. Shortages have forced the hospital to 
delay initiation of treatments for these cancer patients, and alternative treat-
ments are “more toxic and impair fertility in young patients.” Id. A survey by 
Premier Healthcare Alliance found that 80% of hospitals “experienced short-
ages that resulted in a delay or cancellation of a patient care intervention,” 
and 34% suggested this occurred more than six times. CHERICI ET AL., supra 
note 16, at 3. Among the types of procedures delayed due to drug shortages 
were chemotherapy and surgical treatments. See id. 
 30. Approximately eighty-nine percent of hospitals experienced shortages 
that had the potential to cause a medication safety issue or an error in patient 
care, and fifty-three percent suggested this occurred more than six times. 
CHERICI ET AL., supra note 16, at 3. 
 31. Acute myelogenous leukemia (AML) is an example: 
For many patients, AML is a potentially curable disease. Cytarabine 
(Ara-C) is an essential component of treatment for AML, but this drug 
is in short supply today. There is simply no substitute, leaving many 
of our physicians in the situation of telling patients that this poten-
tially curative therapy is not available to them. 
Examining the Increase in Drug Shortages: Hearing Before the H. Comm. on 
Energy & Commerce Subcomm. on Health, 112th Cong. 3 (2011) [hereinafter 
Penley Testimony] (testimony of Charles W. Penley, American Society of Clin-
ical Oncology), available at http://archives.republicans.energycommerce. 
house.gov/Media/file/Hearings/Health/092311%20Drug%20Shortages/Penley_
Testimony.pdf . 
 32. See id. at 3–4. 
 33. Id. 
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hospitals and similar healthcare institutions by forcing these 
facilities to purchase more expensive alternative medications or 
therapies. At a national level, it is estimated that drug short-
ages may cost hospitals over $416 million annually.34 
One factor exacerbating the financial costs associated with 
drug shortages is the activities of gray-market distributors. The 
gray market is a parallel, unofficial supply channel, unintended 
by the original manufacturer, which exhibits a tendency toward 
price gouging.35 When a drug shortage occurs, gray-market dis-
tributors purchase available supplies and re-sell those products 
at significantly inflated prices for whatever the market can 
bear. One study, based on 1,745 gray-market offers, estimates 
that the average markup of gray-market distributors to provid-
ers is 650%, with the highest markups being more than 
4500%.36 While it is not likely that gray-market distributors 
are actually causing drug shortages, their hording of critical 
drugs and exploitation for financial gains exacerbates the se-
verity of the shortage and amplifies its harmful impacts.37 
3. Personnel Impact 
As indicated earlier, drug shortages create significant lo-
gistical burdens for hospitals that must manage the various 
consequences arising from the unavailability of potentially crit-
ical drugs. Adequately adjusting to the reality of a drug short-
age may require the collaboration of an entire host of providers 
and staff.38 The considerable time required by staff to manage 
problems associated with drug shortages not only results in an 
ascertainable financial cost to medical facilities, but it simulta-
neously diverts time away from the intended function of provid-
ing substantive medical care to sick and injured patients.39 
                                                          
 34. Expenses associated with purchasing more expensive generic drugs 
during shortages could be at least $200 million, and the labor costs associated 
with simply managing shortages might be as high as $216 million. Rola 
Kaakeh et al., Impact of Drug Shortages on U.S. Health Systems, 68 AM. J. 
HEALTH-SYS. PHARMACY 1811, 1818 (2011). 
 35. See Examining the Increase in Drug Shortages: Hearing Before the H. 
Comm. on Energy & Commerce Subcomm. on Health, 112th Cong. 8 (2011) 
(testimony of Mike Alkire, Chief Operating Officer, Premier Healthcare Alli-
ance), available at http://archives.republicans.energycommerce.house.gov 
/Media/file/Hearings/Health/092311%20Drug%20Shortages/Alkire_Testimony.
pdf. 
 36. Id. at 9. 
 37. See id. at 7–9. 
 38. See id. at 10–12. 
 39. See id. at 5–7. 
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Drug shortages provoke a cascade of difficulties ranging 
from drug procurement to therapeutic decision-making.40 
Healthcare administrators are forced to determine the validity 
of the shortage and then actively manage the implications af-
fecting their respective facilities.41 Ideally, hospital depart-
ments will assess their ability to meet future patient needs 
based on the existing inventory for a product and subsequently 
develop strategies for therapeutic alternatives.42 
The health system, generally, must make decisions about 
potential alternative therapies or agents that may be used de-
spite the shortage.43 Information about therapeutic changes, 
guidelines, and implementation needs to be conveyed to staff 
and automated systems often need to be updated.44 When there 
is a concern over the availability of a drug, the health system 
may provide specific guidelines for the prioritization of patient 
care, possibly limiting product use to a specific population of 
patients.45 
C. FDA DRUG SHORTAGE PROGRAM 
The FDA’s Drug Shortage Program (DSP) is a division of 
the CDER and was developed in 1991 to respond to growing 
concerns about the public health impact of shortages and “over-
see and facilitate the resolution of all [drug] shortage situa-
tions . . . .”46 
The DSP acquires information about potential drugs short-
ages from an assortment of sources, including internally within 
the FDA and externally from drug manufacturers, although the 
DSP has no regulatory authority to require that manufacturers 
report potential drug shortages unless the drug is medically 
necessary and is being discontinued from a “sole-source.”47 
                                                          
 40. Fox et al., supra note 15, at 1402–03. 
 41. Id. 
 42. See id. 
 43. See id. at 1404. 
 44. Id. 
 45. Id. 
 46. OFFICE OF NEW DRUGS, supra note 3, at 7; Valerie Jensen et al., 
FDA’s Role in Responding to Drug Shortages, 59 AM. J. HEALTH-SYS. 
PHARMACY 1423, 1423 (2002) [hereinafter Jensen et al., FDA’s Role]. 
 47. Jensen et al., FDA’s Role, supra note 46, at 1423–24. The statute spe-
cifically requires that sole-source manufacturers of drugs that are either life-
sustaining, life-supporting, or required in the prevention of a debilitating dis-
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Once the DSP has received a report of a shortage, it must verify 
a disruption in supply and assess the length and severity of the 
shortage. If the DSP determines the drug is “medically neces-
sary,” it posts that information on the FDA website for public 
availability.48 
The DSP may work with manufacturers of medically nec-
essary drug products through the creation of short- and long-
term management plans to alleviate shortages.49 The DSP-
assisted plans may involve appropriate changes in manufactur-
ing sites, processes, or suppliers, as well as the requisite FDA 
review regarding these changes.50 
Overall, the CDER’s available tools for alleviating drug 
shortages include: 
[N]otifying and encouraging manufacturers of the same or similar 
products to increase their production, finding another manufacturer 
to begin production of the product, using regulatory discretion with 
regard to selective release of product when accompanied by appropri-
ate warnings or remedies (e.g., filters for products contaminated with 
particulates), expedited review of an Abbreviated New Drug Applica-
tion (ANDA), expedited review of new manufacturing lines or raw 
material sources to help firms increase production, and regulatory 
discretion with regard to controlled importation of equivalent prod-
ucts approved abroad but not in the United States.51 
The most common approach taken by the FDA has been to re-
quest that companies increase production, followed by regula-
tory discretion, and expedited reviews.52 The FDA does not 
have the authority to require that manufacturers continue pro-
duction during a drug shortage.53 
 
                                                          
ease must provide at least six months of notice prior to any discontinuation in 
manufacture. 21 U.S.C. § 356c(a) (2006). 
 48. Valerie Jensen et al., An Overview of the FDA’s Drug Shortage Pro-
gram, 30 PHARMACY & THERAPEUTICS 174, 174 (2005) [hereinafter Jensen et 
al., An Overview]. 
 49. Id. at 175. 
 50. Id. 
 51. FDA’S APPROACH, supra note 2, at 16. 
 52. Id. Regulatory discretion on the part of the FDA may involve determi-
nations on the level of risk presented by manufacturing or quality problems of 
drugs that are potentially at risk for shortage. For example, low risk events, 
such as incorrect expiration dates on packages, may be more easily circum-
vented at the discretion of the FDA than products with particulate contami-
nants or sterility issues. See Frequently Asked Questions About Drug Shortag-
es, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/ 
DrugSafety/DrugShortages/ucm050796.htm (last updated Aug. 24, 2012). 
 53. FDA’S APPROACH, supra note 2, at 18. 
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D. PROPOSED DRUG SHORTAGE LEGISLATION 
In response to the emerging health crisis posed by increas-
ing drug shortages, there are currently two bills within Con-
gress, one in the House and one in the Senate, each entitled the 
“Preserving Access to Life-Saving Medications Act.”54 The 
House of Representatives’ bill was introduced by Congress-
woman Diana DeGette of Colorado and Congressman Tom 
Rooney of Florida, and the Senate bill was introduced by Sena-
tor Amy Klobuchar of Minnesota and Senator Bob Casey of 
Pennsylvania.55 The primary distinguishing factor between the 
two pieces of legislation is the House bill’s inclusion of biologics 
within the bill’s mandate.56 
Both bills would act to create an early warning system by 
amending the Federal Food, Drug, and Cosmetic Act to provide 
the FDA with the ability to require notification from pharma-
ceutical companies in the event of an interruption in manufac-
turing.57 The bills would require notice at least six months pri-
or to a “discontinuance or planned interruption or adjustment” 
of the manufacture of a drug and as soon as practicable “in the 
case of any other interruption or adjustment.”58 Adjustments 
would include changes “related to the supply of raw materials, 
including active pharmaceutical ingredients; []adjustments to 
production capabilities;[] business decisions that may affect the 
manufacture of the drug . . . ; and []other adjustments as de-
termined appropriate by the Secretary.”59 To enforce compli-
ance on the part of pharmaceutical manufacturers, failure to 
submit a required notification would subject the manufacturer 
                                                          
 54. Preserving Access to Life-Saving Medications Act, S. 296, 112th Cong. 
(2011); Preserving Access to Life-Saving Medications Act of 2011, H.R. 2245, 
112th Cong. 
 55. Press Release, PRNewswire, Capitol Hill Briefing from Nation’s Lead-
ing Patient Advocacy Organization Calls Attention to Impact of U.S. Drug 
Shortage Crisis on Patients’ Ability to Receive Life Saving Treatment (Apr. 24, 
2012), available at http://www.prnewswire.com/news-releases/capitol-hill-
briefing-from-nations-leading-patient-advocacy-organizations-calls-attention-
to-impact-of-us-drug-shortage-crisis-on-patients-ability-to-receive-life-saving-
treatment-148695355.html. 
 56. Compare S. 296 § 2, with H.R. 2246 § 2(b)(4)(B). 
 57. S. 296 § 2(a); H.R. 2245 § 2(b). 
 58. S. 296 § 2(a)–(b); H.R. 2245 § 2(b)(2) (using slightly different language 
than the Senate bill). 
 59. S. 296 § 2(a)(4); H.R. 2245 § 2(a)(3)(B) (using slightly different lan-
guage than the Senate bill). 
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to a civil monetary penalty.60 
Both bills would also require the FDA to establish “evi-
dence-based criteria for identifying drugs that may be vulnera-
ble to a drug shortage.”61 The criteria would be based on the 
“[]number of manufacturers of the drug; []the sources of raw 
material or active pharmaceutical ingredients;[]the supply 
chain characteristics . . . ; and []the availability of therapeutic 
alternatives.”62 If a drug fell within the implemented criteria, 
the Secretary of Health and Human Services would notify the 
manufacturer of the vulnerable drug and collaborate with the 
manufacturer to improve plans to prevent shortages. The 
House bill requires that “with respect to drugs that are vulner-
able to a drug shortage . . . , the Secretary shall collaborate 
with manufacturers and other stakeholders . . . to establish and 
improve continuity of supply plans.”63 The Senate bill provides 
for similar “continuity of operations plans,” although only when 
the vulnerable drugs are “medically necessary.”64 
E. PRESIDENTIAL EXECUTIVE ORDER 
On October 31, 2011, President Obama issued an executive 
order in an effort to address the proliferation of drug shortag-
es.65 The executive order instructs the FDA to employ its exist-
ing authority and administrative tools “to require drug manu-
facturers to provide adequate advance notice of manufacturing 
discontinuances that could lead to shortages” for drugs re-
quired in life support, sustainment, or debilitating diseases, “to 
expand its current efforts to expedite its regulatory reviews, in-
cluding reviews of new drug suppliers, manufacturing sites, 
and manufacturing changes,” and to “communicate to the De-
partment of Justice (DOJ) any findings that shortages have led 
market participants to stockpile the affected drugs . . . .”66 
                                                          
 60. Under H.R. 2245, the penalty shall not “exceed $10,000 for each day 
on which the violation continues, and not to exceed $1,800,000 for all such vio-
lations adjudicated in a single proceeding.” H.R. 2245 § 2(b)(7). Alternatively, 
the Senate bill states that within 180 days of enacting the bill, “the Secretary 
shall promulgate regulations establishing a schedule of civil monetary penal-
ties.” S. 296 § 2(a)(6). 
 61. S. 296 § 2(d)(2); H.R. 2245 § 2(c)(3)(B). 
 62. S. 296 § 2(d)(2)(A); H.R. 2245 § 2(c)(3)(B). 
 63. H.R. 2245 § 2(c)(4). 
 64. S. 296 § 2(d)(3). 
 65. Exec. Order No. 13,588, 3 C.F.R. 281 (2011). 
 66. Id. at 282. 
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II. ANALYSIS 
This section will examine the existing legislation designed 
to address drug shortages, analyze the effectiveness of these 
bills, and suggest additional approaches not provided within 
these pieces of legislation that could be utilized to alleviate and 
prevent future shortages. 
A. PENDING LEGISLATION 
The current legislative proposals within the House and 
Senate represent an essential step toward recognizing and con-
fronting potential drug shortages and mitigating the severity of 
those that occur. However, the existing bills, in their present 
state, fail to provide the comprehensive approach necessary to 
address the multitude of factors that contribute to shortages. 
1. Notification Requirement 
The Preserving Access to Life-Saving Medications Act’s 
creation of an early notification system to ensure manufactur-
ers provide the FDA with important information pertaining to 
discontinuances, interruptions, or adjustments is critical in al-
lowing the FDA to initiate its collaboration with manufacturers 
and utilize available tools to solve preventable drug shortages. 
Historically, drug manufacturers have not been required to 
provide the FDA with regular notification of factors that may 
ultimately contribute to the existence of future drug shortages, 
limiting the agency’s effectiveness in taking preemptive steps 
which could alleviate the risk occurrence.67 From a public 
health perspective, disclosure of potential shortages will pro-
vide doctors and patients with the information necessary to 
make informed decisions relating to the selection of future 
therapeutic approaches or otherwise make arrangements for 
alternative treatments. 
Because current law requires that only manufacturers of 
single source, medically necessary drugs must inform the FDA 
when there is an interruption in production, the FDA’s ability 
                                                          
 67. See Examining the Increase in Drug Shortages: Hearing Before the H. 
Comm. on Energy & Commerce Subcomm. on Health, 112th Cong. 7–8 (2011) 
[hereinafter Colgan Testimony] (testimony of Kevin Colgan, Corporate Direc-
tor of Pharmacy, Rush University Medical Center), available at 
http://archives.republicans.energycommerce.house.gov/Media/file/Hearings/He
alth/092311%20Drug%20Shortages/Colgan_Testimony.pdf. 
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to marshal its full force against shortages is hamstrung by the 
relatively sparse available information.68 Notifications by man-
ufacturers could assist the FDA in making an assessment of 
the potential length and severity of production interruptions 
and prospective shortages, and allow the agency to make de-
terminations as to which remedial steps will be most effective. 
With the expanded notification requirements provided by the 
proposed legislation, the FDA would be better able to cooperate 
with manufacturers to expedite approvals from alternate do-
mestic manufacturing sites, approve importation from foreign 
manufacturing sites that meet cGMP requirements, and ap-
prove new sources for raw materials, to help prevent shortag-
es.69 The FDA may also exercise discretion in alleviating short-
ages by choosing to allow the shipment of drugs that do not 
necessarily create safety issues but are otherwise not compliant 
with FDA regulation.70 Further, the legislation provides an im-
portant enforcement mechanism in the form of monetary penal-
ties for manufacturers that fail to notify the FDA of conditions 
presenting a risk of shortage.71 
                                                          
 68. See id. at 7–8. Manufacturers of non-medically-necessary drugs are 
not required to provide the FDA with notification of any interruption in pro-
duction, but they may choose to do so voluntarily. This similarly applies to 
product discontinuations. See id. at 7. 
 69. All of these approaches are currently available under the existing reg-
ulatory regime, but their effectiveness is limited by the dearth of information 
made available to the FDA by drug manufacturers. See Kate Murphy, How the 
FDA is Addressing Drug Shortages, FIGHT COLORECTAL CANCER (Oct. 5, 
2011), http://fightcolorectalcancer.org/policy_news/2011/10/how_the_fda_is_ad
dressing_drug_shortages. By the agency’s own account, when voluntary notifi-
cations were available, the FDA avoided as many as thirty-eight drug shortag-
es during the year of 2010. Colgan Testimony, supra note 67, at 7. 
 70. Murphy, supra note 69. For example, the FDA may choose to allow the 
shipment of drugs that are mislabeled or packaged improperly. It may approve 
requests to extend drug expiration dates or increase manufacturing capacity. 
Other possibilities may include FDA approval of shipment of drugs that pre-
sent some health risks that can be removed with appropriate steps. Examin-
ing the Increase in Drug Shortages: Hearing Before the H. Comm. on Energy & 
Commerce Subcomm. on Health, 112th Cong. 6–7 (2011) (testimony of Howard 
K. Koh, Assistant Secretary of Health, U.S. Department of Health and Human 
Services), available at http://archives.republicans.energycommerce.house.gov/ 
Media/file/Hearings/Health/092311%20Drug%20Shortages/Kohtestimony.pdf 
(“In [a] recent case . . . , [the] FDA worked with the manufacturer and found 
that if the vials were warmed the crystals would dissolve and the danger to 
patients was mitigated.”). 
 71. See supra note 60 and accompanying text. 
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2. Continuity of Supply Plans 
Further empowering the effectiveness of the notification 
system, the proposed legislation would allow the Secretary to 
“collaborate with manufacturers of drugs . . . to establish and 
improve continuity of operations plans with respect to medical-
ly necessary drugs, as defined by the secretary, so that such 
plans include a process for addressing drug shortages.”72 Alt-
hough the present opacity and lack of information exchange 
impairs the FDA’s ability to engage in meaningful collaboration 
with drug firms, with mandated notification and flow of infor-
mation, the FDA will be better able to implement counter-
measures “such as manufacturing redundancies or backup sup-
plies; more effective communication among FDA, 
manufacturers and other in the supply chain; and finally, de-
velopment of plans that utilize production capabilities of other 
manufacturers either here in the United States or abroad to 
ensure availability of a drug in short supply.”73 
This type of collaboration also facilitates contingency plan-
ning that could, among other approaches, help with the impor-
tation of foreign drugs, establish back-up suppliers for neces-
sary raw materials, and create alternative production sources.74 
Undertaking these preemptive planning steps to ensure conti-
nuity is critical in addressing drug shortage vulnerabilities, 
and the pending legislation would provide the FDA with the 
necessary tools to do so. 
 
                                                          
 72. Preserving Access to Life-Saving Medications Act, S. 296, 112th Cong. 
§ 2(d)(3) (2011). The House bill contains a slightly different mandate. See su-
pra notes 63–64 and accompanying text. 
 73. Colgan Testimony, supra note 67, at 9. Additionally: 
In 2010, FDA worked with APP Pharmaceuticals to help alleviate a 
shortage of propofol, a widely used anesthetic preferred by anesthesi-
ologists because of its excellent safety profile compared to other avail-
able drugs. By enabling the company to work with its German coun-
terpart to import the drug, FDA was able to substantially improve 
product availability after the shortage occurred. Using this example, 
if an acceptable foreign alternative could be identified before a short-
age occurs through establishment of continuity of supply plans for 
vulnerable drugs, then importation could be expedited and the nega-
tive impact of a specific shortage on patient care could be minimized 
or averted. 
Id. 
 74. See id. 
FRISKE_PROOF (DO NOT DELETE) 2/11/2013  11:47 AM 
2013] ADDRESSING PRESCRIPTION DRUG SHORTAGES 535 
3. Identifying Vulnerable Drugs through Evidence-Based 
Criteria 
The proposed legislation would also create an important 
process to identify critical drugs that may be vulnerable to 
shortages through the use of evidence-based criteria.75 Like the 
mandatory notification system, this information will bolster the 
FDA’s ability to collaborate with manufacturers and potentially 
preempt shortages.76 Certain drugs that are manufactured by a 
limited number of firms, or require an API from limited suppli-
ers, are likely among the various drugs that are particularly 
vulnerable to shortages from changes in production or market 
shifts.77 Information regarding vulnerability of particular drugs 
will permit the FDA to undertake efforts to increase overall 
production or rapidly respond to shifting availability and de-
mand.78 Knowledge regarding the potential vulnerability of cer-
tain drugs to shortages may also assist drug distributors and 
healthcare providers to make informed decisions that may im-
pact patient treatments, health, and safety.79 
While these recent legislative efforts would empower the 
FDA to work more closely with entities within the drug supply 
chain and would improve monitoring of drugs that may be vul-
nerable to shortages, the enactments do not provide adequate 
incentives to entice manufacturers into the production of these 
vulnerable drugs and neglect any effort to streamline approval. 
                                                          
 75. S. 296 § 2(d)(2); Preserving Access to Life-Saving Medications Act of 
2011, H.R. 2245, 112th Cong. § 2(c)(3)(B). 
 76. Public information regarding the vulnerability of certain drugs could 
contribute to the occurrence of shortages if gray-market participants or medi-
cal facilities anticipatorily purchase vulnerable drugs based on these identifi-
cation programs. See FDA’S APPROACH, supra note 2, at 29 (noting that “tak-
ing advantage of shortages has emerged as a new business model for some in 
this sector”). While keeping this information private could prevent inadvertent 
shortages through gray-market purchasers, it would defeat one of the im-
portant functions of disseminating relevant information to physicians and 
their patients for treatment planning. These contingencies only further 
demonstrate the importance of effectively dealing with and preventing gray-
market purchasers from exploiting shortages. 
 77. Jensen et al., An Overview, supra note 48, at 175. 
 78. See supra notes 69–70, 73–74 and accompanying text for a discussion 
of potential FDA responses for drugs identified as vulnerable to a shortage. 
 79. Knowledge of vulnerability could allow distributors and providers to 
undergo the complex task of planning for management of a drug shortage. See 
Fox et al., supra note 15, at 1402–05 (outlining the decision-making process 
for managing a drug shortage). 
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B. PROPOSAL FOR ADDRESSING DRUG SHORTAGES 
Much of the proposed legislation is focused on providing 
the FDA with important notifications and information to help 
in the prevention of prospective shortages through the use of 
already existing FDA authority. However, in order to adequate-
ly address the multilayered and complex factors that influence 
drug shortages, the FDA will require more than just notifica-
tion of possible shortages; it must also have more effective reg-
ulatory tools at its disposal to combat these shortages when 
they occur. 
In addition to a robust notification system, effective legisla-
tion should also function to incentivize further manufacture of 
potentially vulnerable drugs and streamline the drug approval 
process during shortages. Providing more stable drug availabil-
ity and resiliency to possible market shifts will reduce the po-
tential for price gouging and reduce exploitation by gray-
market suppliers.80 The following section will elaborate on the 
regulatory tools that could potentially be enacted to assist in 
the prevention and alleviation of drug shortages. 
1. Mandatory Notification Processes 
An integral component of any legislative effort to address 
the growing drug shortage problem will require the creation of 
a notification system to facilitate the flow of relevant infor-
mation to the FDA about discontinuances and interruptions of 
drug production. With knowledge of impending shortages or 
vulnerable drugs, the FDA can employ its existing statutory 
authority to mitigate the probability of occurrence, duration, 
and severity of drug shortages, as discussed previously.81 Con-
comitant with this notification system should be the implemen-
tation of criteria for a priori determination of which drugs may 
                                                          
 80. See supra note 36 and accompanying text for a discussion of price 
gouging by gray-market suppliers. 
 81. See Am. Hosp. Ass’n & Am. Soc’y of Health-Sys. Pharmacists, Options 
for Addressing Drug Shortages, AM. SOC’Y HEATH-SYS. PHARMACISTS 
http://www.ashp.org/DocLibrary/Advocacy/Options-Addressing-Drug-
Shortages.aspx (last visited Sept. 6, 2012) (noting that the FDA can take ac-
tion “to expedite the resolution of quality problems; encourag[e] alternative 
suppliers to ramp up production; expedit[e] internal processes to alleviate or 
prevent shortages, and, in rare cases, institut[e] temporary importation of 
drugs from other counties [sic]”). 
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be at risk for shortages.82 The creation of an identification pro-
cess for vulnerable drugs would assist the FDA in cooperating 
with drug manufacturers to ensure continuity of drug sup-
plies.83 These critical steps are reflected within the proposed 
legislation, under both S. 296 and H.R. 2245, currently pending 
in Congress. 
Encouraging or mandating manufacturers to provide noti-
fication to the FDA when they are acquiring their raw materi-
als from a single source supplier may also help inform the FDA 
of potential shortage risks.84 With this information, the FDA 
may be better able to collaborate with manufacturers and sup-
pliers to ensure that such shortages do not occur.85 The previ-
ously discussed legislation does require the FDA to inquire into 
vulnerability of drugs through evidence-based criteria that con-
siders the sources of raw materials,86 but it does not require 
that manufacturers notify the FDA if they are only able to ac-
quire their raw materials from a single source.87 Alternatively, 
or perhaps in conjunction with manufacturer notification, regu-
lations might seek to require suppliers of APIs and essential 
drug components to provide notifications where such infor-
mation might be relevant to potential shortages. 
A classification system pertaining to the expected length 
and severity of shortages could additionally assist providers 
and patients by allowing them to develop informed choices and 
plans of treatment.88 When important therapeutics are not 
available, physicians may want to know information regarding 
the reasons for the products’ lack of availability, information on 
                                                          
 82. Both S. 296 and H.R. 2245 require the Secretary to implement an evi-
dence-based criteria for identifying vulnerable drugs that considers the num-
ber of manufacturers, sources of raw material or active pharmaceutical ingre-
dients, supply chain characteristics, and the availability of therapeutic 
alternatives. See supra notes 61–62 and accompanying text. 
 83. Am. Hosp. Ass’n & Am. Soc’y of Health-Sys. Pharmacists, supra note 
81. 
 84. Id. 
 85. See Colgan Testimony, supra note 67, at 8 (“This information is, and 
should be considered proprietary, but this lack of transparency hinders the 
development of contingency plans for vulnerable drugs. A requirement that 
manufacturers notify FDA when there is a single source of API may help the 
Agency work with manufacturers to identify backup sources should supply is-
sues arise.”). 
86. See supra notes 61–62 and accompanying text. 
87. For the notification requirements of the proposed legislation, see S. 
296, 112th Cong. § 2(a)(2) (2011); H.R. 2245, 112th Cong. § 2(b) (2011). 
88. Am. Hosp. Ass’n & Am. Soc’y of Health-Sys. Pharmacists, supra note 
81. 
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predicted availability, and potential alternative sources of the 
drug before deciding whether to pursue substitute treatment 
regimens.89 The creation of such a system might also better al-
low the FDA to prioritize its actions by employing greater re-
sources on shortages that present greater health impact due to 
their severity, length, or breadth.90 The system should similarly 
take into account the relative “importance” of each drug by in-
corporating consideration of the availability of alternative drug 
treatments and the severity of the respective disease, illness, or 
necessity in carrying out of medical procedures.91 For example, 
drugs could be classified into three separate categories based 
on how critical they may be to patient treatments: level one—
drugs that cannot be missed for even a single dose or days; lev-
el two—drugs that may be missed for more than a single dose 
or day, but should be reinstituted as soon as possible since they 
reduce long-term complications of disease or reduce intolerable 
symptoms of disease; and level three—drugs that are noncriti-
cal and can be withheld safely for a significant period of time.92 
2. Incentivize Manufacture of Vulnerable Drugs 
Another approach to help prevent drug shortages is to pro-
vide incentives to manufacturers for the production of critical 
drugs that may be in short supply.93 Incentives may encourage 
manufacturers to enter or stay in the market for producing 
these vulnerable drugs through a variety of mechanisms in-
cluding, but not limited to, tax credits or rebates, priority ap-
                                                          
89. CAN. PHARMACISTS ASS’N, DRUG SHORTAGES: A GUIDE FOR 
ASSESSMENT AND PATIENT MANAGEMENT 2 (2010), available at 
http://www.pharmacists.ca/cpha-ca/assets/File/cpha-on-the-
issues/DrugShortagesGuide.pdf. 
90. Am. Hosp. Ass’n & Am. Soc’y of Health-Sys. Pharmacists, supra note 
81. 
 91. See CAN. PHARMACISTS ASS’N, supra note 89, at 4. 
 92. See, e.g., id. at 4–6, for a general classification system for assessing 
drug criticality. In addition, there may be some complicating factors in deter-
mining how critical a drug may be for treatment, such as the difference 
amongst patients receiving these drugs. For example, patients may be receiv-
ing the same drug for different treatments (one that is life threatening and 
one that is not), may be taking multiple drugs that would create prohibitive 
contraindications for alternative drugs, or may be unable to take alternative 
drugs due to intolerable side effects. Id. at 7–8. 
 93. Am. Hosp. Ass’n & Am. Soc’y of Health-Sys. Pharmacists, supra note 
81. 
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proval processes for manufacturers who agree to redundant 
production, or temporary exclusivity of new drug lines in short-
age.94 
Tax incentives could be offered to drug manufacturers in 
an effort to encourage firms to maintain or begin the produc-
tion of vulnerable drugs.95 To ensure a desired and effective 
outcome, these incentives should be crafted to allow for multi-
ple manufacturers to enter and coexist within a single generic 
drug market.96 Providing rebates or credits for companies that 
engage in one of the following activities may help to encourage 
stronger production and allow for a more resilient drug market: 
[Companies that] invest in infrastructure to allow sufficient excess 
inventory of drugs; establish robust continuity of production plans 
(e.g. a manufacturer that keeps extra production lines “clean” and 
ready to start at short notice); commit to produce drugs vulnerable to 
shortage for a specified uninterrupted period of time; [or] re-enter the 
market or increase production when a drug goes on shortage.97 
Tax incentives may help to overcome the inherent profita-
bility problems and subsequent manufacturer aversion to criti-
cal, generic drugs that typically offer less financial upside than 
alternative products with higher profit margins.98 Other ap-
proaches to incentivize the manufacture of vulnerable drugs 
may be to provide those manufacturers with a priority approval 
process99 or to encourage production by permitting a temporary 
exclusivity to a drug product at risk for shortage.100 
                                                          
 94. Colgan Testimony, supra note 67, at 10; Am. Hosp. Ass’n & Am. Soc’y 
of Health-Sys. Pharmacists, supra note 81, at 3. 
 95. See Colgan Testimony, supra note 67, at 10. 
 96. Penley Testimony, supra note 31, at 9. 
 97. Id. 
 98. See id. 
 99. A priority approval process could be implemented for manufacturers 
who agree to institute production redundancies to improve resilience to mar-
ket shifts and limit the occurrence of shortages. For example, currently, many 
manufacturers, (as well as distributors and healthcare organizations) employ 
“just-in-time” inventory procurement approaches where little extra inventory 
supplies are actually on hand at the manufacturing site. These approaches, 
though ostensibly maximizing efficiency and profit, ultimately leave manufac-
turers susceptible to halts in production when supplier shortages occur. See 
CHERICI ET AL., supra note 16, at 2. Efforts to incentivize changes in these 
practices could help reduce drug shortages when supplies are temporarily dis-
rupted. 
 100. See Colgan Testimony, supra note 67, at 10–11. Exclusivity has been 
commonly used by the FDA for “orphan drugs” as a way to reward companies 
who spend resources to develop and produce drugs for the treatment of rare 
conditions. Orphan Drugs, FDA/CDER SMALL BUS. CHRON, (Food & Drug 
Admin., Silver Spring, Md.), July 13, 2012, at 1, available at 
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3. Streamline Drug Approval Process 
Since a clear method for preventing drug shortages is to 
ensure that there are adequate production levels of vulnerable 
drugs, the approval processes involved in manufacture should 
be as smooth and efficient as possible to allow for greater pro-
duction and faster market entry.101 In achieving this goal, the 
FDA should consider implementing a “fast track” approval pro-
cess related to drugs that are experiencing shortages, reex-
amine the current definition of “medically necessary,” and cre-
ate a faster, more responsive, approval process for pre-1938 
drugs.102 
The FDA’s approval process for new production lines, al-
ternative manufacturing sites, and new suppliers of APIs for 
critical drugs in shortage is currently inadequate to deal with 
the rapid onset of drug shortages.103 Unpredictable approval 
timelines foster uncertainty within the production planning 
process for many manufacturers.104 Other requirements, such 
as new drug applications, can further make the process slug-
                                                          
http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/Small
BusinessAssistance/UCM311928.pdf. However, temporary exclusivity may 
itself be problematic in the context of shortages, since it mimics the type of 
manufacturing conditions that frequently pose a significant risk for the occur-
rence of such shortages, i.e., one manufacturer. See supra Part I.A. Balancing 
the length of the exclusivity period may help to reduce this potential problem. 
Exclusivity would also allow for the manufacturer to demand higher prices in 
the absence of competition, which could put greater strain on healthcare facili-
ties and professionals. 
 101. Am. Hosp. Ass’n & Am. Soc’y of Health-Sys. Pharmacists, supra note 
81. 
 102. Id. 
 103. See id. 
 104. See AMANDA RAE KRONQUIST, THE PRESCRIPTION DRUG USER FEE 
ACT: HISTORY AND REAUTHORIZATION ISSUES FOR 2012 at 2 (2011), available 
at http://thf_media.s3.amazonaws.com/2011/pdf/bg2634.pdf. The author ex-
plains: 
An ambiguous and inconsistent approval process prevents Americans 
from accessing new therapies and drugs that save lives. The medical 
product development path in the U.S. has become more challenging, 
costly, and unpredictable as the previous reauthorizations have piled 
on regulations that detract from the FDA’s primary task of providing 
innovative medical products to the American public as quickly and 
safely as possible. 
Id. “A new regulatory model that provides drug companies with transparency, 
clarity, and certainty is needed to continue developing innovative products 
without a convoluted review process.” Id. at 10. 
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gish and impair manufacturers from being able to rapidly enter 
into the production of a drug, potentially lengthening or exac-
erbating the shortage.105 
The implementation of “fast track” approval processes that 
apply specifically to drugs that are vulnerable or currently ex-
periencing a shortage may allow the FDA and manufacturers to 
become more responsive to unpredictable or rapid shifts that 
induce shortages. Further, including other regulatory compo-
nents, such as mandating manufacturing redundancies when 
approving applications for vulnerable drugs could help ensure 
there is a robust availability of any given drug product.106 Steps 
may generally include improving the overall efficiency of the 
process by altering current approval protocols, giving priority 
treatment to approval requests related to shortages, and in-
creasing agency resources to deal with these requests.107 
Reexamination of the current statutory definition of “medi-
cally necessary” could be another prudent step to augment the 
FDA’s authority to act in a significant number of shortages.108 
When alternative treatments are available, a drug does not fall 
within the category of “medically necessary.” However, the def-
inition does not inquire into the nature of the alternative 
treatments and their potential side-effects.109 The definition 
further does not consider how widespread the use of a particu-
lar drug may be.110 Expanding the definition to include analysis 
of substantial side-effects, prevalence of use, and the availabil-
                                                          
 105. See Am. Hosp. Ass’n & Am. Soc’y of Health-Sys. Pharmacists, supra 
note 81. While fast-tracked approval processes may ultimately serve to put 
drugs onto the market faster, such processes may subject patients to drug 
products that have undergone potentially inferior testing for safety or effec-
tiveness. One possible way to increase the speed of the approval process with-
out interfering with its goals of ensuring drug safety and effectiveness may 
simply be to provide the FDA with increased resources that could be diverted 
to expediting these approvals during times of shortages or when shortages are 
impending, i.e., vulnerable drugs. See id. As with nearly all the approaches 
discussed, increased funding of the FDA may be necessary to effectively im-
plement these additional regulations. Given the current economic straits and 
trend toward budget cuts, increased funding of the FDA may be a politically 
unpalatable approach and may make dealing with future shortages difficult. 
 106. Id. at 2–3. 
 107. Id. at 1–2; Awi Federgruen, The Drug Shortage Debacle—And How to 
Fix It, WALL ST. J., Mar. 2, 2012, at A13. Expedited approval of ANDA, sup-
plemental applications, and production lines are the most obvious options. 
 108. Am. Hosp. Ass’n & Am. Soc’y of Health-Sys. Pharmacists, supra note 
81. 
 109. Id. 
 110. OFFICE OF NEW DRUGS, supra note 3, at 8. 
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ity and relative effectiveness of alternative treatments may 
have the effect of increasing the number of “medically neces-
sary” drugs and providing the FDA greater discretion to act 
when these drugs fall into shortages. 
Creating an expedited approval process for pre-1938 drugs 
may also alleviate drug shortages.111 Many pre-1938 drugs are 
widely used in therapies but continue to be unapproved. Many 
of these drugs possess a continuing history of safe use but have 
since fallen victim to increasing FDA scrutiny and been classi-
fied as unapproved.112 Prioritizing, shortening, or making the 
process less demanding for these critical drugs may foster 
manufacturing and ensure availability by limiting the regula-
tory hurdles necessary for their production.113 
Many critical drugs also fall within the ambit of Drug En-
forcement Agency (DEA) regulations and are subject to manu-
facturing quotas due to classification as controlled substanc-
es.114 The limits imposed by these quotas can impair the FDA’s 
                                                          
 111. Colgan Testimony, supra note 67, at 10–11; Am. Hosp. Ass’n & Am. 
Soc’y of Health-Sys. Pharmacists, supra note 81. 
 112. Am. Hosp. Ass’n & Am. Soc’y of Health-Sys. Pharmacists, supra note 
81. Note that: 
Congress originally permitted these [pre-1938] drugs to continue to be 
manufactured without the additional demonstrations of their safety 
and effectiveness otherwise required in the 1938 and 1962 FDA laws. 
However, increasing [c]ongressional scrutiny over the past decade has 
led [the]FDA to deem these drugs “unapproved[,]” and manufacturers 
have been required to enter into a new drug application (NDA) pro-
cess for many of these drugs. 
Id. Addtionally: 
Several drug shortages (e.g., concentrated morphine sulfate solution, 
levothyroxine injection) have been precipitated by actual or anticipat-
ed action by the FDA as part of the Unapproved Drugs Initiative, 
which is designed to increase enforcement against [pre-1938] drugs 
that lack FDA approval to be marketed in the United States. . . . 
Some participants noted that the cost and complexity of completing a 
New Drug Application (NDA) for those unapproved drugs is a disin-
centive for entering or maintaining a market presence. 
Drug Shortages Summit Summary Report, AM. SOC’Y HEALTH SYS. 
PHARMACISTS (Nov. 5, 2010), 
http://www.ashp.org/drugshortages/summitreport. 
 113. Am. Hosp. Ass’n & Am. Soc’y of Health-Sys. Pharmacists, supra note 
81, at 2. One obvious way to expedite the approval process of these drugs is by 
limiting the evidentiary burden for approval placed on prospective manufac-
turers, based on a strong and continued history of safe use. Efforts might also 
include eliminating or reducing the NDA user fee altogether. 
 114. Id. 
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ability to collaborate with manufacturers and prevent in-
creased production during times of shortages. To reduce the 
negative impact of these quotas, increased collaboration be-
tween the FDA and DEA and an expedited process for altering 
manufacturing quotas should be implemented to allow for 
quicker, more flexible, responses to potential drug shortages.115 
4. Nonlegislative Actions 
There are many nonlegislative actions that can be taken to 
help foster better responses to the risk of drug shortages and 
ensure continued availability of these critical medical products. 
Actions may be taken to help identify factors that contribute to 
the success or failure of FDA efforts to prevent shortages, iden-
tify quality issues in manufacturing practices that have affect-
ed drug shortages, encourage manufacturers to develop contin-
gency plans in the event of supply disruption, provide 
additional staffing resources for the FDA, develop networks for 
early warning of drug shortages to the healthcare system, and 
improve communication between FDA investigators and the 
CDER.116 
Some stakeholders have suggested that creating a national 
stockpile reserve for critical therapies may help buffer against 
drug shortages.117 However, given that these therapies are pre-
sumably already in limited supply or potentially vulnerable to 
shortage, the hoarding of these drugs may have adverse conse-
quences on the market, manufacturers, and distribution pric-
es.118 For such an approach to be applicable, the targeted drugs 
would need to be readily available in excess of current condi-
tions. This task would require government agencies to deter-
                                                          
 115. Id. 
 116. FDA’S APPROACH, supra note 2, at 5–6. 
 117. Similar approaches with vaccines and antibiotics have been undertak-
en as preventative steps against counterterrorism and natural disasters. Stra-
tegic National Stockpile (SNS), CTRS. FOR DISEASES CONTROL AND 
PREVENTION, http://www.cdc.gov/phpr/stockpile/stockpile.htm (last updated 
Mar. 8, 2012) (“CDC’s Strategic National Stockpile (SNS) has large quantities 
of medicine and medical supplies to protect the American public if there is a 
public health emergency (terrorist attack, flu outbreak, earthquake) severe 
enough to cause local supplies to run out.”). 
 118. See Drug Shortages Summit Summary Report, supra note 112. Addi-
tionally, it is possible that some drugs may not be amenable to long-term stor-
age and could not be effectively stockpiled due to their likelihood of perishing. 
Even if most drugs were suitable for stockpiling, storage alone does not ad-
dress the underlying causes of the shortages and would only serve as a tempo-
rary buffer. 
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mine which drugs are potentially vulnerable to shortage and 
acquire stockpiles of those products without negatively influ-
encing the market.119 Whatever the value of governmental 
hoarding of important drug products, this approach would not 
be available or effective in the short term to address existing or 
pending crises. 
III. CONCLUSION 
The increasing prevalence and severity of critical drug 
shortages in recent years poses a significant threat to public 
health that demands immediate attention. Among the types of 
therapies affected are essential cancer drugs, anesthesia drugs, 
and others necessary to sustain life or prevent serious disease. 
The impact of these drug shortages is detrimental to pa-
tient safety and health and induces significant financial hard-
ship on hospitals and healthcare facilities that must struggle to 
manage the uncertainty associated with unavailable, yet criti-
cal, drugs. 
The factors contributing to the existence of drug shortages 
are disparate, varied, and often unrelated, and therefore must 
be addressed by a comprehensive and multifaceted approach. 
The current legislation proposed in Congress takes several key 
steps toward providing the FDA with the ability to adequately 
manage these problems, but it falls short of addressing many 
underlying problems that have influenced these shortages. 
Policymakers need to balance the short-term concerns of 
addressing the current drug shortage crises with prudent steps 
toward general prevention in the long term, while being simul-
taneously cognizant of how regulations may directly or indirect-
ly influence the behavior of the market. In order to adequately 
and effectively address the proliferation of drug shortages, leg-
islators and regulators should not only consider early notifica-
tion systems to assist the FDA in its responses to impending 
drug shortages, but they also must work to create a more ro-
bust drug market through incentives and streamlined approval 
processes. A drug manufacturing infrastructure that is resilient 
and can simultaneously respond more rapidly to capricious 
market events is essential to eliminating the upward trend in 
drug shortages. 
                                                          
 119. See id. 
